# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k060027   
B. Purpose for Submission: Clearance of new device   
C. Measurand: Controls and Calibrators for dehydroepiandrosterone sulfate (DHEA-S) assay   
D. Type of Test: Not applicable. This submission is for clearance of controls and calibrators.   
E. Applicant: BIOKIT S.A.

# F. Proprietary and Established Names:

ARCHITECT DHEA-S CALIBRATORS (A-F) AND CONTROLS (LOW, MEDIUM AND HIGH)

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>Single (Specified)</td><td rowspan=2 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1660,</td><td rowspan=2 colspan=1>75 CLINICALCHEMISTRY (CH)</td></tr><tr><td rowspan=1 colspan=1>Analyte Controls(Assayed AndUnassayed) (JJX)</td><td rowspan=1 colspan=1>Quality controlmaterial (assayedand unassayed).</td></tr><tr><td rowspan=1 colspan=1>Calibrator,Secondary (JIT)</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1150,Calibrator.</td><td rowspan=1 colspan=1>75 CLINICALCHEMISTRY (CH)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

# Calibrators

The ARCHITECT® DHEA-S Calibrators are for the calibration of the ARCHITECT i System when used for the quantitative determination of DHEA-S in human serum and plasma.

# Controls

The ARCHITECT® DHEA-S Controls are for the verification of the accuracy and precision of the ARCHITECT i System when used for the quantitative determination of DHEA-S in human serum and plasma.

2. Indication(s) for use:

# Calibrators

The ARCHITECT® DHEA-S Calibrators are for the calibration of the ARCHITECT i System when used for the quantitative determination of DHEA-S in human serum and plasma.

# Controls

The ARCHITECT® DHEA-S Controls are for the verification of the accuracy and precision of the ARCHITECT i System when used for the quantitative determination of DHEA-S in human serum and plasma.

3. Special conditions for use statement(s):

For Prescription use only.

# 4. Special instrument requirements:

The ARCHITECT® DHEA-S Calibrators and Controls are designed to be used for the calibration of the ARCHITECT® DHEA-S on the ARCHITECT® $i 2 0 0 0$ or $i 2 0 0 0 \mathrm { s r }$ instrument platform. The instrument system was 510k cleared through submission number K983212.

# I. Device Description:

Calibrator A contains human serum nonreactive for HBsAg, anti-HIV-1/HIV-2, HIV NAT, anti-HBc, HCV NAT, and anti-HCV. Calibrators B-F contain purified synthetic DHEA-S in human serum nonreactive for ${ \mathrm { H B s A g } }$ , anti-HIV-1/HIV-2, HIV NAT, antiHBc, HCV NAT, and anti-HCV. Preservative: Sodium azide. Each DHEA-S Calibrator kit contains 6 bottles of Calibrators (a $2 . 0 \mathrm { m l }$ fill volume per bottle) with the following DHEA-S concentrations: 0, 5, 12, 60, 300, and $1 5 0 0 ~ \mu \mathrm { g / d L }$ .

The controls contain purified synthetic DHEA-S in human serum nonreactive for HBsAg, anti-HIV-1/HIV-2, HIV NAT, anti-HBc, HCV NAT, and anti-HCV. Preservative: Sodium azide. Each DHEA-S control kit contains 3 bottles of controls (a $4 . 0 \mathrm { m l }$ fill volume per bottle) with the following target concentrations (low, Medium, and High): 10, 100, and $1 0 0 0 ~ \mu \mathrm { g / d L }$ .

# J. Substantial Equivalence Information:

<table><tr><td>Predicate</td><td>K935806</td></tr><tr><td>Describe the item being compared</td></tr><tr><td colspan="2">DPC IMMULITE  DHEA-SO4 Calibrators and Controls</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities - Calibrators</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The ARCHITECT® DHEA-SCalibrators are for thecalibration of the ARCHITECTi System when used for thequantitative determination ofDHEA -S in human serum andplasma.</td><td rowspan=1 colspan=1>DHEA-SO4 For the quantitativedetermination ofdehydroepiandrosterone sulfate inserum.</td></tr><tr><td rowspan=1 colspan=1>SystemMethodology</td><td rowspan=1 colspan=1>ChemiluminescentMicroparticleImmunoassay (CMIA)</td><td rowspan=1 colspan=1>Chemiluminescent a solid phaseenzyme immunoassay</td></tr><tr><td rowspan=1 colspan=1>Assay Protocols</td><td rowspan=1 colspan=1>Competitive assay</td><td rowspan=1 colspan=1>Competitive assay</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>DHEA-S (synthetic) in humanserum with preservative.(SodiumAzide)</td><td rowspan=1 colspan=1>Lyophilized DHEA -SO4 in humanserum with preservative</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences - Calibrators</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">ARCHITECT i System</td><td colspan="1" rowspan="1">Immulite 2000 Analyzer</td></tr><tr><td colspan="1" rowspan="1">CalibrationRange/Levels</td><td colspan="1" rowspan="1">0, 5, 12, 60, 300, and 1500μg/dL</td><td colspan="1" rowspan="1">15-1,000 μg/dL</td></tr><tr><td colspan="3" rowspan="1">Similarities - Controls</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The ARCHITECT® DHEA-SCalibrators are for thecalibration of the ARCHITECTi System when used for thequantitative determination ofDHEA -S in human serum andplasma.</td><td colspan="1" rowspan="1">DHEA-SO4 For the quantitativedetermination ofdehydroepiandrosterone sulfate inserum.</td></tr><tr><td colspan="1" rowspan="1">SystemMethodology</td><td colspan="1" rowspan="1">ChemiluminescentMicroparticle Immunoassay(CMIA)</td><td colspan="1" rowspan="1">Chemiluminescent a solid phaseenzyme immunoassay</td></tr><tr><td colspan="1" rowspan="1">Assay Protocols</td><td colspan="1" rowspan="1">Competitive assay</td><td colspan="1" rowspan="1">Competitive assay</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">DHEA-S (synthetic) in humanserum with preservative.(SodiumAzide)</td><td colspan="1" rowspan="1">Lyophilized DHEA -SO4 in humanserum withpreservative</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences - Controls</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>ARCHITECT i System</td><td rowspan=1 colspan=1>Immulite 2000 Analyzer</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Single constituent, DHEA -S(synthetic) in human serumwith preservative. (SodiumAzide)</td><td rowspan=1 colspan=1>Multi constituent, Human serumbased tri-level control containingover 25 constituents commonlymeasured by immunoassay.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>10, 100, and 1000 µg/dL</td><td rowspan=1 colspan=1>Three levels, see package insert formeasured values</td></tr><tr><td rowspan=1 colspan=1>Assay sampletype</td><td rowspan=1 colspan=1>Serum and plasma</td><td rowspan=1 colspan=1>Serum</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable):   

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>Interference Testing in Clinical Chemistry; Approved Guideline (CLSI EP 7-A) Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline</td></tr><tr><td>(CLSI EP5-A)</td></tr></table>

<table><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=2 colspan=1>Guidance for Industry - Abbreviated510(k) Submissions for In VitroDiagnostic Calibrators; Final</td><td rowspan=2 colspan=1>OIVD</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/calibrator.html</td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Points to Consider GuidanceDocument on Assayed and UnassayedQuality Control Material; Draft</td><td rowspan=1 colspan=1>OIVD</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/99.html</td></tr></table>

# L. Test Principle:

Not applicable. This submission is for calibrators and controls.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Not applicable b. Linearity/assay reportable range: Not applicable c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Primary calibrators and controls are prepared gravimetrically by adding Synthetic DHEA-S obtained from a commercial source to a human serum-based matrix. The secondary calibrators and controls are also prepared gravimetrically by adding Synthetic DHEA-S obtained from a commercial source to a human serum-based matrix. Relative light unit (RLU) testing is performed and RLU values are compared to the corresponding Primary Calibrator or Control. The sponsor’s acceptance criteria is that RLU variation must be within $+ / - 1 . 5 \%$ .

Target values for secondary calibrators are 0, 5, 12, 60, 300, and $1 5 0 0 ~ \mu \mathrm { g } / \mathrm { d L }$ DHEA-S.   
Target values for secondary controls are 10, 100, and $1 0 0 0 ~ \mu \mathrm { g / d L }$ DHEA-S.

The DHEA-S Calibrators and Controls are stable for 6 months if stored at 2 to $8 \ : ^ { \circ } \mathrm { C }$ . Protocols and acceptance criteria for stability testing were described and found to be acceptable.

d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable   
f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.